OBJECTIVES: Characterize treatment responsiveness in chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) patients with diabetes mellitus (DM). METHODS: We performed a retrospective chart review of CIDP subjects assessed between 1997 and 2013 and compared treatment response rates in those with and without DM, using different sets of criteria. RESULTS: 99 CIDP patients were included, 34 CIDP+DM and 65 CIDP-DM patients, both having similar treatment response rates. CIDP patients fulfilling European Federation of Neurological Societies/Peripheral Nerve Society (EFNS/PNS) criteria had higher treatment response rates. Responders fulfilled a higher number of American Academy of Neurology (AAN) and EFNS/PNS criteria and had a higher number of demyelinating features in the total cohort and in CIDP-DM but not in CIDP+DM patients. CIDP+DM responders, however, had unique electrophysiologic characteristics. CONCLUSION: Fulfilling EFNS/PNS and AAN criteria, and higher number of demyelinating features, are associated with higher treatment response rates in CIDP-DM but not in CIDP+DM patients, implying the need for adjusting current criteria to predict treatment response rates in CIDP-DM patients.
OBJECTIVES: Characterize treatment responsiveness in chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) patients with diabetes mellitus (DM). METHODS: We performed a retrospective chart review of CIDP subjects assessed between 1997 and 2013 and compared treatment response rates in those with and without DM, using different sets of criteria. RESULTS: 99 CIDP patients were included, 34 CIDP+DM and 65 CIDP-DMpatients, both having similar treatment response rates. CIDP patients fulfilling European Federation of Neurological Societies/Peripheral Nerve Society (EFNS/PNS) criteria had higher treatment response rates. Responders fulfilled a higher number of American Academy of Neurology (AAN) and EFNS/PNS criteria and had a higher number of demyelinating features in the total cohort and in CIDP-DM but not in CIDP+DMpatients. CIDP+DM responders, however, had unique electrophysiologic characteristics. CONCLUSION: Fulfilling EFNS/PNS and AAN criteria, and higher number of demyelinating features, are associated with higher treatment response rates in CIDP-DM but not in CIDP+DMpatients, implying the need for adjusting current criteria to predict treatment response rates in CIDP-DMpatients.
Entities:
Keywords:
chronic inflammatory demyelinating polyradiculoneuropathy; criteria; demyelination; diabetic neuropathy; type 1 diabetes; type 2 diabetes
Authors: Alon Abraham; Majed Alabdali; Mohammad Qrimli; Hana Albulaihe; Ari Breiner; Carolina Barnett; Hans D Katzberg; Leif E Lovblom; Bruce A Perkins; Vera Bril Journal: PLoS One Date: 2015-10-13 Impact factor: 3.240
Authors: Vera Bril; Christopher M Blanchette; Joshua M Noone; M Chris Runken; Deborah Gelinas; James W Russell Journal: J Diabetes Complications Date: 2016-05-10 Impact factor: 2.852
Authors: Ari Breiner; Carolina Barnett Tapia; Leif Erik Lovblom; Bruce A Perkins; Hans D Katzberg; Vera Bril Journal: Neurol Neuroimmunol Neuroinflamm Date: 2019-07-10
Authors: Monica Alcantara; Mylan Ngo; James de la Cruz; Deepak Menon; Carolina Barnett-Tapia; Hans Katzberg; Vera Bril Journal: Front Neurol Date: 2022-04-26 Impact factor: 4.003
Authors: Alon Abraham; Hana Albulaihe; Majed Alabdali; Mohammad Qrimli; Ari Breiner; Carolina Barnett; Hans D Katzberg; Leif E Lovblom; Bruce A Perkins; Vera Bril Journal: PLoS One Date: 2015-11-06 Impact factor: 3.240